Bonn, Germany

Marion Goldeck

This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn. Active years: 2016-2021.

USPTO Granted Patents = 5 

% Patents Active = 100.0


 

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2021

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Marion Goldeck: Innovator in RIG-I Ligands

Introduction

Marion Goldeck is a prominent inventor based in Bonn, Germany. She has made significant contributions to the field of biochemistry, particularly in the development of RIG-I ligands. With a total of 5 patents to her name, her work has implications for pharmaceutical applications.

Latest Patents

One of her latest patents focuses on RIG-I ligands and methods for producing them. This invention relates to new triphosphate-modified oligonucleotides that may act as RIG-I ligands. Additionally, it introduces a new method that allows for the synthesis and purification of these oligonucleotides in high yield and purity, making them suitable for pharmaceutical applications.

Career Highlights

Marion Goldeck is affiliated with the Rheinische Friedrich-Wilhelms-Universität Bonn, where she conducts her research and development. Her innovative work has positioned her as a key figure in her field, contributing to advancements in molecular biology and therapeutic applications.

Collaborations

Throughout her career, Marion has collaborated with notable colleagues, including Jasper Van Den Boorn and János Ludwig. These partnerships have enhanced her research efforts and expanded the impact of her inventions.

Conclusion

Marion Goldeck's contributions to the field of biochemistry, particularly through her patents on RIG-I ligands, highlight her role as an influential inventor. Her work continues to pave the way for advancements in pharmaceutical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…